{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-012602","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.315280+00:00","generated_at":"2026-06-17T01:36:29.439630+00:00","sec_items":["1.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biofrontera settles litigation with Biofrontera AG, expands board, amends rights plan","bullets":["Settlement resolves Delaware Chancery lawsuit and challenges to Biofrontera AG's January 2023 shareholder meeting.","Board expands from 5 to 6; Biofrontera AG appoints one Class I director; will add seventh director for 2023 annual meeting.","Rights Agreement amended: Biofrontera AG's beneficial ownership threshold raised from 20% to 29.96%.","Related Party Transactions Committee established to approve all deals between Biofrontera Inc. and Biofrontera AG.","Standstill: Biofrontera AG cannot buy additional shares without committee OK; must vote with Board through 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-012602","json":"https://secwatch.observer/filing/0001493152-23-012602.json","markdown":"https://secwatch.observer/filing/0001493152-23-012602.md","text":"https://secwatch.observer/filing/0001493152-23-012602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223012602/0001493152-23-012602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223012602/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:36:29.439630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0d93a76f299a5f54ad528f7b2cc56d352ed61f8","claim":"Biofrontera Inc. entered into Settlement Agreement with Biofrontera AG valued at settlement of disputes related to stockholder meetings and director nominations (effective 2023-04-11).","evidence_excerpt":"On April 11, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), and each member of its Board of Directors, in their individual capacities, entered into a settlement agreement (the “Settlement Agreement”) with Biofrontera AG, a significant stockholder of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858685/000149315223012602/0001493152-23-012602-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Biofrontera AG"},{"label":"Value","value":"settlement of disputes related to stockholder meetings and director nominations"},{"label":"Effective","value":"2023-04-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}